Prospective Community Cancer Clinics-based Approach to Optimize Germline Testing in Cancer Patients in Rural Setting to Address Racial Disparities: UNIversal Germline Testing in the communitY (UNITY) Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- Invitae Corporation
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Rate of Pathogenic Germline Variants (PGV)
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
This study seeks to enroll participants who have a diagnosis of a solid tumor cancer and are willing to undergo germline genetic testing for cancer risk. At baseline, patients will be asked to provide 2 types of blood samples: 1 tube for clinical genetic testing and 2 tubes for future research use. A tumor sample from a previous resection or biopsy will also be obtained and sent to the sponsor. The clinician will be asked to provide relevant medical history and demographic information to the sponsor in the form of electronic case report forms.
Detailed Description
This study seeks to enroll adult participants who have a diagnosis of a solid tumor cancer and are willing to undergo germline genetic testing for cancer risk using Invitae's Multi-Cancer gene panel. At baseline, patients will be asked to provide 2 types of blood samples: 1 tube for clinical genetic testing and 2 tubes for future research use. A tumor sample from a previous resection or biopsy will also be obtained and sent to the sponsor. The participant's clinician will be asked to provide relevant medical history and demographic information to the sponsor in the form of electronic case report forms at 3 timepoints: 1 month following the results of the participants genetic testing, one year post genetic testing, and 2 years post genetic testing.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient has consented to germline genetic testing
- •Patient has a histologically confirmed diagnosis of a solid tumor cancer
- •Patient is willing to release previously collected tissue sample
- •Patient is willing to provide research blood samples
- •Patient must be at least 18 years of age
Exclusion Criteria
- •Patient is unable to consent.
- •Patient with hematologic malignancy
Outcomes
Primary Outcomes
Rate of Pathogenic Germline Variants (PGV)
Time Frame: Will be assessed at baseline only.
Assess rate of PGVs in the trial participants using Invitae's 84 gene multi-cancer gene panel.